Burden of Influenza at Emergency Department (ED) Level in European Countries
NCT ID: NCT04244500
Last Updated: 2020-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2500 participants
OBSERVATIONAL
2020-01-27
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Burden of Influenza at Emergency Department Level : BIED
NCT04153331
Retrospective Observational Study on the Epidemiological Characteristics of Influenza Patients
NCT04110990
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
NCT02478905
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
NCT01022931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary:
\- Measure the proportion of non-traumatic emergency department (ED) visits infected with influenza during the peak of the influenza season
Secondary:
* Describe the demographic and medical profile of influenza-related and non-influenza-related visits
* Identify socio-demographic or other risk factors associated with ED visit outcome
* Describe the influenza positivity rate among ED visits for different causes
* Measure the proportion of influenza positive patients without classical ILI symptoms
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Influenza
Influenza testing
swab sampling
Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
swab sampling
Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants and/or guardian providing informed consent and/or assent, as appropriate, to participate.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Klinikum Ernst von Bergmann Potsdam
UNKNOWN
Klinikum Suedstadt, Rostock
UNKNOWN
Sanofi Pasteur, a Sanofi Company
INDUSTRY
University of Rostock
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. med. Micha Loebermann
Deputy head of Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rostock
Rostock, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMR893958
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.